- Home
- CYCN vs BFRI Comparison
CYCN vs BFRI Comparison
Compare CYCN & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYCN | BFRI |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 16.3M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYCN | BFRI |
|---|---|---|
| Price | $3.36 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | 90.6K | ★ 625.4K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.26 | ★ 67.70 |
| EPS | N/A | ★ N/A |
| Revenue | $2,074,000.00 | ★ $41,705,000.00 |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.70 | ★ 11.75 |
| 52 Week Low | $1.03 | $0.57 |
| 52 Week High | $8.48 | $1.66 |
Technical Indicators
Market Signals| Indicator | CYCN | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 55.97 |
| Support Level | $3.04 | $0.78 |
| Resistance Level | $3.42 | N/A |
| Average True Range (ATR) | 0.49 | 0.10 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 23.67 | 42.81 |
Price Performance
Historical ComparisonAbout CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.